Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duopharma Biotech BhdXKLS:7148 +0.81%82 5-Year Yield-on-Cost % is 2.60 as of Jul. 23, 2026, which is 37% above its 10-year median of 1.90. GuruFocus rates XKLS:7148 with a GF Score™ of 82/100 and a GF Value™ of RM1.54 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 513 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 52.44% on this metric.
Duopharma Biotech Bhd's yield on cost for the quarter that ended in Mar. 2026 was 2.60.
The historical rank and industry rank for Duopharma Biotech Bhd's 5-Year Yield-on-Cost % or its related term are showing as below:
XKLS:7148'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.97 Med: 1.9 Max: 3.42
Current: 2.6
During the past 13 years, Duopharma Biotech Bhd's highest Yield on Cost was 3.42. The lowest was 0.97. And the median was 1.90.
XKLS:7148's 5-Year Yield-on-Cost % is ranked better than 52.44% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs XKLS:7148: 2.60
Duopharma Biotech Bhd (XKLS:7148) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Duopharma Biotech Bhd 5-Year Yield-on-Cost % Related Terms
XKLS:7148 vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's 5-Year Yield-on-Cost % falls into.
Duopharma Biotech Bhd 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Duopharma Biotech Bhd (XKLS:7148) has a 5-Year Yield-on-Cost % of 2.60 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Duopharma Biotech Bhd and its competitors. This is 37% above median its historical median of 1.90. Over the past decade, Duopharma Biotech Bhd's 5-Year Yield-on-Cost % has ranged from 0.97 to 3.42. According to the industry distribution chart, Duopharma Biotech Bhd ranks #244 out of 513 companies in the Drug Manufacturers industry, placing it in the top 47.6%.
Is Duopharma Biotech Bhd's 5-Year Yield-on-Cost % too high?
Duopharma Biotech Bhd's current 5-Year Yield-on-Cost % of 2.60 is 37% above median its 10-year median of 1.90. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 3.42. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.27. Duopharma Biotech Bhd's value of 2.60 is 14.5% above this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #244 out of 513 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #244 out of 513 companies for 5-Year Yield-on-Cost %. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.27. Duopharma Biotech Bhd's value of 2.60 is 14.5% above this benchmark. Historically, Duopharma Biotech Bhd's own 5-Year Yield-on-Cost % has ranged from 0.97 to 3.42 over the past decade. While the company's 10-year median is 1.90 vs. the industry median of 2.27, Duopharma Biotech Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current 5-Year Yield-on-Cost % of 2.60 is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current 5-Year Yield-on-Cost % is 2.60, which is 37% above median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.54, compared to a current price of RM1.24 — trading 19.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.60, which is 37% above median its 10-year median of 1.90 and 14.5% above the Drug Manufacturers industry median of 2.27. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current 5-Year Yield-on-Cost % is 2.60 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.24 is trading 19.5% below its estimated GF Value™ of RM1.54.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
5-Year Yield-on-Cost %: 2.60 (37% above median its 10-year median of 1.90)
GF Value™: RM1.54 vs. price of RM1.24 (19.5% below fair value)
Industry Position: 14.5% above the Drug Manufacturers median (#244 of 513)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score
Get the complete analysis for XKLS:7148
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
